Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.
| Revenue (Most Recent Fiscal Year) | $705.00M |
| Net Income (Most Recent Fiscal Year) | $-453.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 10.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 15.94 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -29.04% |
| Net Margin (Trailing 12 Months) | -28.25% |
| Return on Equity (Trailing 12 Months) | -45.29% |
| Return on Assets (Trailing 12 Months) | -8.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.99 |
| Inventory Turnover (Trailing 12 Months) | 0.69 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.70 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.04 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 159.39M |
| Free Float | 155.25M |
| Market Capitalization | $10.07B |
| Average Volume (Last 20 Days) | 3.23M |
| Beta (Past 60 Months) | 0.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |